Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $23.7 million, above the midpoint of guidance but down from $24.6 million in Q4 2024 [12] - Gross margin was 59.77%, up 260 basis points from 57.1% in Q4 2024, marking the highest gross margin in the last seven quarters [12][13] - Adjusted EBITDA increased by 27% year-over-year to $3.8 million in Q4 2025 [14] - Full year revenue was $86.6 million, down from $94.1 million in 2024, primarily due to tariffs and delayed NIH funding [15] - Full year adjusted EBITDA increased by 12.5% to $8.1 million from $7.2 million in 2024 [16] Business Line Data and Key Metrics Changes - The company experienced a favorable mix shift towards higher margin product lines, contributing to improved financial results [7] - The new product innovation pipeline includes scalable platforms like SoHo Telemetry and BTX for bioproduction, expected to drive growth [9] - Approximately 55% of revenue is recurring, with a focus on higher margin consumables and services [9] Market Data and Key Metrics Changes - Q4 revenues in the Americas were down 2% year-over-year, driven by lower pharma and academic sales [16] - In Europe, Q4 revenues were down 12% year-over-year due to lower academic sales [17] - In China and the Asia Pacific, Q4 revenues were up 10% year-over-year, attributed to growth in preclinical distribution [17] Company Strategy and Development Direction - The company is evolving from a traditional life science tools provider to a leader in translational science, focusing on bridging in vivo and in vitro research [8] - Key strategic priorities include leading the translational science bridge, accelerating high margin innovation, expanding consumables and recurring revenue, and maintaining operational excellence [9][10] - The company aims for low single-digit revenue growth and high single-digit adjusted EBITDA growth in 2026, driven by higher margin NPI growth [10] Management's Comments on Operating Environment and Future Outlook - Management noted that the life science industry is undergoing a fundamental shift, with drug development remaining inefficient [7] - The company expects to see a positive impact from NIH funding approvals towards the end of Q1 and into Q2 [26][27] - The company is well-positioned to manage volatility due to its diversified geographic footprint and improved cost structure [10] Other Important Information - The company completed a comprehensive refinancing that extended debt maturity to 2029 and reduced annual debt service by $3 million [4][19] - The company has reinstated bonuses and merit-based compensation for employees in 2026 after being suspended in 2025 [21] Q&A Session Summary Question: How quickly do you think NIH approval will improve the academic environment? - Management expects a positive impact towards the end of Q1 and into Q2 as grant submissions are approved [26][27] Question: What is the expected growth for key products like BTX and Mesh MEA in 2026? - Both products are expected to grow in double digits this year [28] Question: What is the status of the company's backlog? - The company ended the year with the highest backlog in over two years and maintains a positive outlook on it [36] Question: How is the demand for products on the pharmaceutical drug development side? - The pharma and biotech market is showing growth, which is factored into the company's guidance for the year [38]

A notable development in the tokenized IP-Rights RWA ecosystem.BeatSwap’s Licensing-to-Earn (L2E) architecture integrates onchain licensing verification with IPL (IP Licensing Index) minting, which is triggered when users engage with licensed tracks.This framework connects verifiable usage-based licensing events to a monthly IPL snapshot mechanism, which will determine proportional BTX distribution following the early December TGE.It is a technically robust approach that links real IP-Rights activity with t ...